Top Trending Stocks Today — Friday, June 26, 2026 – Friday’s session is delivering everything at once: a biotech short squeeze, a 20%+ FDA winner, a chip ETF riding Micron’s earnings afterglow, a quantum computing name surging on White House tailwinds, and an AI infrastructure small-cap nobody was watching until this week.

The following tickers are dominating trending sentiment board right now — ranked by conversation volume and social momentum. Here’s the full breakdown on every name, with catalysts, prices, technicals, and what traders are watching.

Today’s Trending Stocks at a Glance

#1 — SLS: SELLAS Life Sciences Group | The Short Squeeze Nobody Can Ignore

This is the most talked-about stock on Wall Street’s retail circuit today — and for good reason.

• Price today: ~$10.50, with an intraday high of $10.88 (day range: $10.47–$10.88)
• 52-week range: $1.39 – $11.06
• YTD performance: +140%
• Short interest: Nearly 33% of float (Koyfin data, as of June 15) — an all-time high, up sharply from 25.5% at the start of April

Why It’s Trending

Three things landed simultaneously:

1. Executive Severance Restructuring — Buyout Signal? SELLAS filed changes to severance agreements for CEO Angelos Stergiou, CFO John Burns, and Chief Development Officer Dragan Cicic. In biotech, this type of “change-of-control” filing typically precedes acquisition discussions. Traders are connecting the dots.

2. Phase 3 REGAL Trial — One Catalyst Away The Phase 3 REGAL trial evaluating Galinpepimut-S (GPS) in Acute Myeloid Leukemia patients is at 78 of 80 events required to trigger the final overall survival analysis. The readout is effectively imminent — and if GPS shows a survival benefit in relapsed/refractory AML, SLS would have one of the most significant oncology data points of the year.

3. Record Short Interest = Squeeze Fuel With 33% of the float shorted and the stock nearing its 52-week high of $11.06, any positive headline from the REGAL trial could trigger a violent short squeeze. SLS shares have already surged from $8 to over $10 this week alone.

Key Metrics

• Q1 2026 cash: $107.1 million
• Additional warrant proceeds (April–May): $28.7 million
• Market cap evolution: $73 million (early 2024) → $1.5 billion+ (mid-2026)
• Analyst coverage: Thin — WSJ/FactSet shows 2 Buy ratings, avg. target ~$10 (now lagging the stock)
• Secondary catalyst: SLS009 (CDK9 inhibitor, Phase 2) — topline data expected Q4 2026

Bottom line: SLS is a pure catalyst play. If REGAL hits, it could double from here. If it misses, the downside is severe. The squeeze mechanics make this one of the most asymmetric setups in the market right now.

#2 — SOXX: iShares Semiconductor ETF | Chip Comeback in Full Force

The AI-driven chip supercycle is back in the spotlight after Micron’s blowout Q3 earnings sent shockwaves through the sector.

• Price today: $624.82 (day range: $598.83 – $638.47)
• 52-week range: $232.33 – $655.95
• YTD performance: +89%
• 1-year return: +182.31%
• AUM: $43.26 billion
• Technical signal: Strong Buy (Investing.com daily signal); MACD turned positive June 18

Why It’s Trending

Micron Technology’s blowout Q3 results (EPS $25.11 vs. $20.78 consensus) sent ripples through the entire semiconductor supply chain. ASML, LRCX, and AMAT all moved higher on Thursday specifically because Micron’s results validate the AI memory chip upcycle — and SOXX holds every major name.

Top Holdings Today:

• 3-month net flows into SOXX: $4.92 billion
• 1-year net flows: $6.98 billion
• Upcoming catalyst: SK Hynix’s planned $29.4 billion U.S. listing — if successful, it deepens institutional attention on the memory chip trade and could re-rate SOXX holdings higher

Tom Lee of Fundstrat called Thursday’s chip selloff (in non-AI names like AAPL and MSFT) a “textbook buying opportunity” for semiconductor names.

#3 — MLTX: MoonLake Immunotherapeutics | Friday’s Biggest Winner

The day’s standout mover. MoonLake is up over 20% — and the catalyst is a genuine regulatory breakthrough.

• Premarket surge: +20.15% to $23.08 (Benzinga Pro data)
• 52-week context: Stock was trading around $21 prior to this week’s news
• Analyst avg. price target: $27.62 (+30% implied upside from recent prices)
• Cash position: $357.9 million (as of March 31, 2026)

The Catalyst: FDA Clears BLA Path for Sonelokimab in HS

The U.S. FDA confirmed that existing trial data from MIRA, VELA-1, and VELA-2 is sufficient to support a Biologics License Application (BLA) for Sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa (HS) — without requiring any new pivotal trials.

This eliminates one of the biggest clinical uncertainties hanging over the stock.

Phase 3 VELA Week-52 Results (released June 21–22):

• 67.2% of patients achieved HiSCR75 (pooled VELA-1 + VELA-2)
• 33.1% achieved HiSCR100 (complete lesion control)
• 26% achieved IHS4-100 (complete resolution of inflammatory lesions)
• Results are broadly consistent across both VELA trials
• Long-term outcomes compare favorably vs. all competing HS therapies in prior Phase 3 studies

Timeline:

• BLA submission target: End of September 2026
• Competitive advantage: HS competitor Insmed halted its own HS program after the CEDAR study missed — effectively clearing the field for MoonLake

Analyst Reactions

• Clear Street: “Blockbuster potential” for SLK — labeled HS profile as “highly competitive”
• H.C. Wainwright: Raised price target to $45 (Buy rating maintained)
• Multiple analysts reiterating $30–$33 price targets intraday

The $200M Share Offering

MoonLake priced an upsized public offering of $200 million (raised from $150M) at $20/share — 9 million Class A shares plus pre-funded warrants for 1 million additional shares — closing around June 25. This war chest funds the SLK commercialization runway.

The HS opportunity: Hidradenitis suppurativa affects approximately 1% of the global population and is significantly underpenetrated by effective therapies. Analysts see a multi-billion dollar peak sales opportunity for a best-in-class agent.

🔗 Read the VELA-2 trial results at MoonLake IR

#4 — QS: QuantumScape Corp. | Honda Deal Keeps Solid-State Battery Story Alive

• Recent catalyst: +15.8% surge on June 18 after announcing a solid-state battery development agreement with Honda
• Current move: +0.62% today as the Honda deal continues to draw interest
• Why it matters: Honda deepening its commitment to QuantumScape’s solid-state battery technology signals growing OEM confidence in the tech

Key thesis: QuantumScape’s lithium-metal solid-state batteries promise dramatically higher energy density and faster charging vs. conventional lithium-ion. Honda’s deal is a validation event that puts QS back on the EV battery roadmap after a period of quiet. Bullish options flow has been consistently flagged on this name since the announcement.

🔗 See QuantumScape investor updates at QuantumScape IR

#5 — INFQ: Infleqtion Inc. | Quantum Computing Gets White House Tailwinds

• Category: Quantum technology — computing, sensing, national security
• Recent surge: Up +12% following news of Trump administration acceleration of quantum development programs
• Today: +0.44%, consolidating recent gains
• Name change: Formerly ColdQuanta, Inc. — rebranded as Infleqtion in January 2026

Why It’s Trending

The Trump administration has moved to fast-track quantum computing as a national security and economic competitiveness priority — directly benefiting Infleqtion, which provides:

• Neutral atom quantum computing
• Quantum sensing (including GPS-denied navigation for defense applications)
• Quantum atomic clocks and RF receivers

The national security angle is particularly powerful right now: GPS-denied quantum sensing is a direct application for the ongoing Middle East military situation. Government contract momentum is the key driver.

The quantum sector at large is experiencing a re-rating event in 2026, with Quantinuum (QNT) also surging after HPE tapped it for hybrid quantum computing infrastructure. INFQ is part of this broader re-rating wave.

🔗 For background on the U.S. National Quantum Initiative, visit quantuminitiative.org

#6 & #7 — OXY + USO: Energy Names Stay in the Conversation

OXY (Occidental Petroleum) — $50.90 Today

• Day range: $50.47 – $50.93
• 52-week range: $38.80 – $67.45
• 52-week average price: $48.29

OXY remains in the Stocktwits conversation primarily because of two forces: Warren Buffett’s continued ownership through Berkshire Hathaway, and the ongoing crude oil volatility narrative. A fresh insider purchase by OXY’s top boss was disclosed June 24 — a notable vote of confidence near current levels.

With crude retreating toward $74–75/barrel (from a wartime high of $114), OXY’s pure-play Permian Basin and DJ Basin exposure makes it more sensitive to oil price moves than integrated supermajors like XOM or CVX.

USO (United States Oil Fund)

The USO ETF — which tracks WTI crude futures — is +0.50% today and remains a top-trending proxy for traders who want direct oil price exposure without holding individual energy stocks. As the Iran peace deal stabilizes and crude normalizes, USO positioning reflects the market’s current reading of the geopolitical risk premium: declining, but not gone.

#8 — ASML: The Chip Equipment King Gets Multiple Analyst Upgrades

ASML is the backbone of the entire semiconductor industry — and Wall Street keeps repricing it higher.

• Recent all-time high: $1,743.27
• 1-year analyst consensus: Strong Buy (44 analysts)
• Average 12-month price target: $1,740.56

Why It’s Trending Today

ASML rose alongside the broader chip equipment cohort on Thursday (LRCX, AMAT) after Micron’s earnings validated that the AI memory upcycle is real and accelerating. Analysts noted that Micron’s blowout results imply robust demand for the EUV and deep UV lithography tools that only ASML can supply.

Recent Analyst Price Target Moves:

• 2025 revenue: $32.67 billion (+15.58% YoY)
• 2025 earnings: $9.61 billion (+26.91% YoY)
• EUV leadership: ASML is the sole supplier of extreme ultraviolet lithography systems for leading-edge chips — a structural monopoly in the AI buildout

BofA expects ASML’s 2027 order book to be fully subscribed when the company reports Q2 results on July 15 — a potential “narrative pivot” toward its 2028 earnings power. That date is a major catalyst to watch.

The Elon Musk $55 billion Terafab vision (pitched at an ASML event in early June) keeps ASML at the center of the most ambitious AI chip manufacturing thesis on the planet.

#9 — WYFI: WhiteFiber Inc. | The AI Data Center Build-Out Play Flying Under the Radar

WhiteFiber is up +6.52% today and has been on a steady run since securing a landmark AI funding deal this week.

• Catalyst: $100 million delayed-draw senior secured term loan for AI and HPC expansion, expandable to $150 million
• Structure: Bit Digital (majority owner) + B. Riley as co-lenders; B. Riley taking a $20M advance slice to fund Phase 1 completion
• Project: Enovum NC-1 AI/HPC data center in Madison, North Carolina — the flagship asset behind the ticker

Financials Snapshot

• Debt-to-equity: 0.71
• Current ratio: 2.8 (solid near-term liquidity)
• Price-to-sales: ~6.97 (growth infrastructure pricing)
• Free cash flow: Deeply negative — all capital going into data center build-out

This is a “build now, profit later” story. WYFI is not being bought for current earnings — it’s being bought because AI-driven demand for HPC compute capacity is structural, the facility is funded, and a strategic heavyweight (Bit Digital) is backing the build. The flexible draw structure means WYFI doesn’t pay dead interest — it pulls capital as milestone phases complete.

For retail traders, the NC-1 facility in Madison, North Carolina is the tangible anchor. Watch for Phase 1 completion updates as the next key catalyst.

#10 — RXT: Rackspace Technology | The 653% YTD Comeback Nobody Predicted

One of the most stunning stock turnarounds of 2026 belongs to a company most investors had written off.

• YTD return 2026: +653.36%
• Recent price: ~$5.92 (June 15 close), up from sub-$1 levels earlier in the year
• All-time high: $26.07 (April 2021)

The Turnaround Story

Three events transformed Rackspace in 2026:

1. Q1 Earnings Beat (May 7): Stock jumped 64% in a single session from ~$2.26 to $3.72 after Q1 results. While EPS came in at -$0.06 vs. -$0.03 consensus, full-year guidance of -$0.20 to -$0.15 vs. -$0.03 consensus signaled management confidence — and the AMD deal became the story.

2. AMD AI Infrastructure Partnership (June 16): Rackspace signed an expanded partnership with AMD to build a new category of governed enterprise AI infrastructure. This isn’t just an MOU — it’s a product development commitment that directly aligns RXT with the enterprise AI deployment wave.

3. 15% Workforce Reduction (June 16): Announced alongside the AMD deal, the layoffs signal a leaner, AI-focused Rackspace shedding legacy managed services weight to accelerate the AI infrastructure pivot.

• Technical signal: 4 buy signals, neutral overall; 60% uptrend since June 9 (+60.3%)
• Resistance levels: $7.87, then $9.22
• Support levels: $3.52, then $2.18

RXT is a classic high-reward, high-risk turnaround play. Up 653% YTD sounds extraordinary — but the stock is still 77% below its 2021 all-time high. For those who believe enterprise AI deployments will flood managed infrastructure providers, Rackspace is the small-cap high-beta bet.

Today’s Market Context

These trending names don’t exist in a vacuum. Here’s the macro backdrop shaping Friday’s session:

• S&P 500: ~7,357 (flattish); Nasdaq: under pressure after 4-day losing streak; Dow: up ~0.2%
• Dominant theme: Rotation from mega-cap tech (AAPL -6%, MSFT -3% Thursday) into semiconductors, biotechs, and energy
• PCE inflation: Hit 4.1% annualized in May — the highest since October 2023 — keeping rate hike fears elevated
• Bitcoin: ~$61,000 range; Gold: Testing $4,000 support; Brent crude: ~$74.75/barrel
• Micron (MU): +16% Thursday post-earnings is the single most important move this week — it’s the reason SOXX and ASML are trending and the reason SanDisk (SNDK) surged 21%

Watch List for Next Week

For more real-time market coverage, visit TruthsandNews.com

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Always complete independent due diligence prior to executing equity trades.

About The Author

Kasia Davis

See author's posts